Contact UsCareers
Top bar

Science explained

We believe we have zeroed in on the Notch pathway and its role as a tumorigenic driver in some patients with rare and aggressive cancers.

Using our deep understanding of the Notch pathway, we are developing potential therapies to address the underlying key drivers of tumor growth in patients where gamma secretase inhibitors (GSIs) of Notch may make a difference.

What’s our approach to treating rare cancers?

Target

Target

indications in which activated Notch pathway is known to be a tumorigenic driver

Focus

Focus

on indications with high unmet medical need and pursue development in an efficient manner

Expand

Expand

addressable patient population by developing diagnostic tools that cover all four Notch receptors, genetic mutations and gene rearrangements

Our Mechanism of Action, explained

How does our technology work in helping to inhibit the Notch signaling pathway?
See the difference between normal and tumorigenic signaling of Notch, and how our gamma secretase inhibitors (GSIs) AL101 and AL102 can impact Notch signaling.

Normal:
The Notch pathway is involved in embryonic development and in the renewal and maintenance of adult tissues.

Normal

The Notch pathway is involved in embryonic development and in the renewal and maintenance of adult tissues.

moa1a

Tumorigenic

In cancers, Notch is known to serve as a critical facilitator in processes such as cellular proliferation, survival, migration, invasion, drug resistance and metastatic spread, all of which contribute to tumorigenesis and cancer progression.

al102_al102

With Treatment

Inhibition of Notch by γ-secretase inhibitors (GSIs) such as AL101/AL102 turns off the Notch pathway activation.

About our investigational therapies

Doctor talking with patient in doctors office

AL101

Our investigational lead candidate is a novel, injectable, potent and selective small molecule gamma secretase inhibitor (GSI). AL101 is currently being studied in Phase 2 ACCURACY clinical trial for recurrent/metastatic adenoid cystic carcinoma (R/M ACC) for patients bearing Notch-activating mutations. In addition, we intend to commence Phase 2 clinical trials of AL101 for the treatment of triple negative breast cancer (R/M TNBC) and T-cell acute lymphoblastic leukemia (R/R T-ALL).

AL102

Ayala is developing AL102 for the treatment of desmoid tumors, which are rare, disfiguring and often debilitating types of soft tissue tumors. We intend to commence a Phase 2 trial of AL102. Evaluation of AL102 as an inhibitor of the Notch pathway for additional indications is ongoing.


Ayala is also collaborating with Novartis to develop AL102 for the treatment of multiple myeloma (MM) in combination with Novartis’ B-cell maturation antigen (BCMA) targeting therapies. Studies of MM treatment have entered Phase 1 of clinical trials. 

Shot of a compassionate doctor comforting a young woman in a hospital waiting room